A randomized, open label trial to assess the steady state pharmacokinetics of Avastin [bevacizumab] given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.

Trial Profile

A randomized, open label trial to assess the steady state pharmacokinetics of Avastin [bevacizumab] given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2012

At a glance

  • Drugs Bevacizumab; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 01 Nov 2011 Results published in Cancer Chemotherapy and Pharmacology.
    • 01 Dec 2008 Actual end date reported as May 2007 by ClinicalTrials.gov.
    • 20 Oct 2008 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top